PTPN11 and cancer: For example, while combined SHP2 and MEK inhibition has shown efficacy in some cancer models, some toxicity was observed in human participants.58,60 The combination of BRAFi and SHP2i evaluated here, however, shows promise for improved tolerability due to the specificity of dabrafenib for BRAF V600E, potentially improving the therapeutic index.